ABBOTT LABORATORIES — Director's Dealing 2017

Feb 22, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2017-02-17

Reporting Person: CAPEK JOHN M (Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-02-17	Common shares without par value	A	14273	—	Acquired	288797	Direct
2017-02-21	Common shares without par value	M	93400	$26.6973	Acquired	382197	Direct
2017-02-21	Common shares without par value	S	93400	$45	Disposed	288797	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-02-17	Option (right to buy)	$44.40	A	98714	Acquired	2027-02-16	Common shares (98714)	Direct
2017-02-21	Option (right to buy)	$26.6973	M	93400	Acquired	2018-02-14	Common shares (93400)	Direct

Footnotes

F1: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,905 on 2/17/2018, 32,904 on 2/17/2019, and 32,905 on 2/17/2020.

F3: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.